Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Archives of Dermatological Research|July 18, 2024
Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligoYuji Yamaguchi, Elena Peeva, Ester Del Duca, et al.
Allergy|November 17, 2025
Large-Scale Blood Proteomic Analysis Across Different Inflammatory Skin Conditions Reveals Extensive Immune Dysregulation With Distinct Biomarker ProfilesJacob W Glickman, Eden David, Neda Shokrian, et al.
Allergy|April 5, 2021
High-dimensional analysis defines multicytokine T-cell subsets and supports a role for IL-21 in atopic dermatitisTali Czarnowicki, Hyun Je Kim, Axel P Villani, et al.
Italian Journal of Dermatology and Venereology|September 17, 2020
Arsenic and chromium levels in hair correlate with actinic keratosis/non-melanoma skin cancer: results of an observational controlled studyGiusy Schipani, Ester Del Duca, Giuseppe Todaro, et al.
The Journal of Allergy and Clinical Immunology|October 4, 2020
Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalitiesHelen He, Ester Del Duca, Aisleen Diaz, et al.
Dermatology (Basel, Switzerland)|November 8, 2018
Lesions Mimicking Melanoma at Dermoscopy Confirmed Basal Cell Carcinoma: Evaluation with Reflectance Confocal MicroscopyFrancesca Peccerillo, Victor Desmond Mandel, Francesca Di Tullio, et al.
Experimental Dermatology|September 20, 2024
Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analysesElena Peeva, Yuji Yamaguchi, Zhan Ye, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|August 18, 2021
Transcriptomic Profiling of Tape-Strips From Moderate to Severe Atopic Dermatitis Patients Treated With DupilumabDaniela Mikhaylov, Ester Del Duca, Caroline Meyer Olesen, et al.
Allergy|September 30, 2022
Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseasesAna B Pavel, Ester Del Duca, Julia Cheng, et al.
JAMA Dermatology|June 21, 2023
Hyperactivation of the JAK2/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic CellulitisJohanna Morot, Ester Del Duca, Marine Chastagner, et al.
Pageof 12